期刊文献+

小剂量氢氯噻嗪肠溶片的制备及体外释放度测定

The preparation and the release in vitro determination of small dosage of hydrochlorothiazide enteric-coated tablets
原文传递
导出
摘要 目的制备小剂量氢氯噻嗪肠溶片,并对其体外释放度进行测定。方法选用适宜的辅料制备氢氯噻嗪片芯,用Ⅱ号丙烯酸树脂为肠溶包衣材料制备肠溶片,采用紫外分光光度法测定氢氯噻嗪肠溶片的含量和释放度。结果在包衣增重6%,包衣转速20~30r/min,热处理时间为2小时时,制备的肠溶衣在盐酸溶液中2小时不裂片不崩解,在磷酸钠缓冲液中释放度符合2005版中国药典要求。结论采用该工艺制备氢氯噻嗪肠溶片,方法可行,重现性好,制备的肠溶片在盐酸溶液中和磷酸缓冲液中的释放度符合2005版中国药典标准。 Objective Manufacturing small dosage of hydrochlorothiazide enteric-coated tablets and determining its release in vitro.Method Choosing condign accessories to manufacture hydrochlorothiazide tablets,and selecting the model No.II acrylic acid polymers as enteric-coating material to produce enteric-coated tablets,and then,mensurating the contains and the release rate of hydrochlorothiazide enteric-coated tablets with the uv-speetrophotometric method.Result The manufactured enteric-coated tablets,when its coating gains 6% weight and has the rotational speed between 20 and 30 r/min,and the heat-treatment time reaches 2h,don't split and collapse in the hydrochloric acid solution,furthermore,its release rate in the sodium diphosphate solution meets the standard of the chinese pharmacopoeia 2005 edition.Conclusion This technics,introduced to produce the hydrochlorothiazide enteric-coated tablets,is practical and has great reproducibility,moreover,when the produced enteric-coated tablets are put in the hydrochloric acid solution or sodium diphosphate solution,its release rate is up to the standard of the chinese pharmacopoeia 2005 edition.
出处 《辽宁医学杂志》 2012年第5期221-224,共4页 Medical Journal of Liaoning
基金 2010年盐城市医学科技科研课题项目:编号YK2010042
关键词 氢氯噻嗪 肠溶片 释放度 hydrochlorothiazide enteric-coated tablet release rate
  • 相关文献

参考文献7

  • 1蔡伟,李健,姜曜,张美和,纪冬霞.不同剂量氢氯噻嗪治疗原发性高血压的疗效观察[J].中国医院药学杂志,2011,31(3):229-231. 被引量:8
  • 2Wright JM. Choosing a first-line drug in the management of el- evated blood preasure: what is the evidence? 1: Thiazide[M] CMAJ,2000,163:57.
  • 3Wright JM,Lee CH,Chambers GK. Systematic review of anti- hypertensive therapies : does the evidence assist in choosing a first-line drug[J]. CMAJ, 19 9 9,161 : 2 5.
  • 4Weir MR, Flack JM, applegate WB. Tolerablility, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics[J]. Am Jmed. 1996, 101 : 83.
  • 5王文.巾国高血压防治指南(2009年基层版).http://www.365heart.corn.
  • 6中国药典.二部[S].2005.附录:29.
  • 7中华医学会心血管病学分会商血压学组.利尿荆治疗高血压的中国专家共识[J].中华商血压杂志,2011,03:217.

二级参考文献10

  • 1吴寿岭,孙丽霞,赵海燕,王桂玲,李云,王黎光,贺文昌,刘福山,刘克俭.长期小剂量氢氯噻嗪的降压疗效观察[J].中华心血管病杂志,2006,34(5):396-399. 被引量:33
  • 2Shah SU, Anjum S, Littler WA. Use of diuretics in cardiovascular disease : (2) hypertension[J]. Postgrad Med J. 2004,80: 271- 276.
  • 3Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alphablocker as first-step antihypertensive therapy; final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLAHT) [J]. Hypertension, 2003.42 : 239 -246.
  • 4Wright JM. Choosing a first line drug in the inanagement of elevated blood preasure: what is the evidence? 1 : Thiazide[J]. CMAJ, 2000, 163 : 57-60.
  • 5Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapics: does the evidence assist in choosing a first-line drug[J]. CMAJ, 1999.161:25-32.
  • 6Weir MR. Flack JM, Applegate WB. Tolerahlility, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics[J]. Am J Med. 1996,101 : 83S-92S.
  • 7王文.中国高血压防治指南(2009年基层版)[EB/OL].http://www.365heart.com.
  • 8.中国药典二部[S].,2005年版.68.
  • 9陈灏珠.实用内科学[M]12版.北京:人民卫生出版社,2005.1746-1750.
  • 10中华人民共和国卫生部高血压联盟(中国).中国高血压防治指南(2005年修订版)[M].北京,人民卫生出版社,2006:7.

共引文献104

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部